Summary
This Alnylam Pharmaceuticals, Inc. (ALNY) 10-Q filing for the quarter ended March 31, 2017, highlights the company's continued focus on its novel RNA interference (RNAi) therapeutics. Alnylam is advancing a pipeline across three strategic therapeutic areas: Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases, with a stated goal of having three marketed products and ten RNAi therapeutic clinical programs by the end of 2020. The company reported a significant increase in net revenues from collaborators, primarily driven by its partnerships with Sanofi Genzyme and The Medicines Company (MDCO). Financially, Alnylam continues to incur substantial operating losses, consistent with its R&D-intensive business model. While R&D expenses saw a slight decrease year-over-year, general and administrative expenses increased significantly due to investments in commercial and medical affairs infrastructure in preparation for potential product launches. The company maintains a robust cash position but faces ongoing risks associated with drug development, regulatory approvals, competition, and the need for future financing. The most advanced candidate, patisiran, is expected to report Phase 3 data in mid-2017, with potential regulatory filings planned by year-end if results are positive.
Financial Highlights
39 data points| Revenue | $18.96M |
| R&D Expenses | $86.98M |
| Operating Expenses | $125.47M |
| Operating Income | -$106.51M |
| Net Income | -$107.29M |
| EPS (Basic) | $-1.25 |
| Shares Outstanding (Basic) | 86.03M |
Key Highlights
- 1Alnylam reported a substantial increase in net revenues from collaborators, up to $18.96 million from $7.34 million in the prior year's quarter, primarily due to increased activity under agreements with Sanofi Genzyme and MDCO.
- 2Despite increased collaboration revenues, the company continued to experience significant operating losses, with a net loss of $107.29 million for the quarter, compared to $102.97 million in the same period last year.
- 3Research and development (R&D) expenses decreased by approximately $9.3 million year-over-year, partly due to lower stock-based compensation and reduced external services, though manufacturing expenses increased for late-stage trials.
- 4General and administrative (G&A) expenses nearly doubled, increasing by approximately $17.4 million, driven by investments in commercial and medical affairs headcount in anticipation of future product launches.
- 5Patisiran, the most advanced RNAi therapeutic candidate for hereditary TTR-mediated amyloidosis (hATTR amyloidosis), is expected to report top-line data from its APOLLO Phase 3 study in mid-2017, with planned regulatory submissions by year-end if data are positive.
- 6The company maintained a strong liquidity position with $171.1 million in cash and cash equivalents at the end of the quarter, though this represents a decrease from the prior year-end.
- 7Alnylam continues to emphasize its proprietary GalNAc-conjugate delivery platform and its broad intellectual property portfolio, which is considered essential to its business strategy.